Mepolizumab
Product Specifications
UNSPSC Description
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma[1][2].
Target Antigen
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/mepolizumab.html
Purity
98.00
Solubility
H2O
Smiles
[Mepolizumab]
References & Citations
[1]Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151.|[2]Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797.|[3]P Zia-Amirhosseini, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P9945/Mepolizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P9945/Mepolizumab-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
196078-29-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6219981-01 0.1 mL
WNK2 (WNK Lysine deficient Protein Kinase 2, KIAA1760, NY-CO-43, P/OKcl.13, PRKWNK2, SDCCAG43) (MaxLight 550)
Ask
View Details MBS6219981-02 5x 0.1 mL
WNK2 (WNK Lysine deficient Protein Kinase 2, KIAA1760, NY-CO-43, P/OKcl.13, PRKWNK2, SDCCAG43) (MaxLight 550)
Ask
View Details 